MANKIND PHARMA
Back to Income Statement
|
MANKIND PHARMA Last 5 Year Revenue History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Net Sales | ₹14,278 Cr | ₹12,207 Cr | ₹10,260 Cr | ₹8,749 Cr | ₹7,782 Cr |
What is the latest Revenue of MANKIND PHARMA ?
| Year | Revenue |
|---|---|
| Mar2026 | ₹14,278 Cr |
| Mar2025 | ₹12,207 Cr |
| Mar2024 | ₹10,260 Cr |
| Mar2023 | ₹8,749 Cr |
| Mar2022 | ₹7,782 Cr |
How is Revenue of MANKIND PHARMA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2026 | ₹14,278 Cr | 16.96 | |
| Mar2025 | ₹12,207 Cr | 18.98 | |
| Mar2024 | ₹10,260 Cr | 17.27 | |
| Mar2023 | ₹8,749 Cr | 12.44 | |
| Mar2022 | ₹7,782 Cr | - | |
Compare Revenue of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹102,194.8 Cr | -5.5% | -2.2% | -5.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,870.0 Cr | -1.4% | 2.4% | 17.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹220,946.0 Cr | 12.2% | 23.1% | 21.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,907.0 Cr | 2.4% | 5.3% | 41.7% | Stock Analytics | |
| CIPLA | ₹118,674.0 Cr | 1.7% | 0.7% | -3.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,648.7 Cr | 3% | -14.9% | -10.2% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | -5.5% |
-2.2% |
-5.1% |
| SENSEX | 2.4% |
1.5% |
-4.3% |
You may also like the below Video Courses